Drugs / AUR101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04855721 | May 2021 → Nov 2022 | psoriasis | Aurigene Discovery Technologies Limited | Completed | No outcome recorded |
| Phase 2 | NCT04207801 | Jan 2020 → Mar 2021 | psoriasis | Aurigene Discovery Technologies Limited | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-08-19 | Auron Therapeutics, Inc. | Results Auron Presents Preclinical Data at American Chemical Society Annual Meeting aurontx.com ↗
As shown with AUR101, degradation of KAT2A/KAT2B inhibits growth and induces cell state change towards a more terminally differentiated state across both AML and SCLC models. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-08-19 | Auron Therapeutics, Inc. | Auron Presents Preclinical Data at American Chemical Society Annual Meeting aurontx.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AUR101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04855721 ↗ |
| Action | Inhibit | “Inhibitor of RORγ” NCT04207801 ↗ |
| Route | Oral | “Oral ROR-gamma inverse agonist” NCT04855721 ↗ |